Lantern Pharma Inc. Q3 FY2025 earnings call

• Clinical Progress: LP-184 Phase Ia trial validated AI-driven precision medicine approach; Starlight Therapeutics had FDA Type C meeting for pediatric CNS cancer trial; LP-300 and LP-284 had preliminary data presentations. - AI Platform Advancements: RADR platform's modules showed commercial potential; withZeta platform for rare cancers integrated data for faster drug discovery. - Operational Management: Clinical operations in Asia adjusted for cost reduction and efficiency; Taiwan CRO services shifted, Japan team supplemented. - Financials: Q3 2025 R&D expenses ~$2.4M, G&A expenses ~$1.9M, net loss ~$4.2M, cash ~$12.4M; funds raised via ATM sales agreement.

1. LP-184 Phase Ia: Successfully achieved all primary endpoints, with a 48% clinical benefit rate in evaluable cancer patients at or above the therapeutic threshold. Marked tumor reductions were observed in patients with specific DNA damage repair mutations. 2. LP-300 HARMONIC: Preliminary Phase II data presented at the Japan Lung Cancer Society, with a more comprehensive data update planned via webinar in December. 3. LP-284: Clinical data showcased at the Lymphoma, Leukemia and Myeloma Congress, generating interest in combination therapy; preclinical models show potential in autoimmune diseases like lupus. 4. RADR AI platform: PredictBBB module with 94% accuracy in BBB permeability prediction; LBx-AI liquid biopsy platform with 86%-90% accuracy in predicting treatment response in non-small cell lung cancer. 5. withZeta: Multi-agentic AI platform for rare cancers, integrating rare cancer databases and ontologies to accelerate rare cancer drug development.

• Host KOL-hosted scientific webinar on LP-184 Phase Ia details on November 20, 2025. - Provide interim patient follow-up and additional clinical data for LP-300 in December 2025. - Discuss commercial developments of AI platform modules, including withZeta for rare cancer development in upcoming quarters. - Plan to submit IND for pediatric CNS program in the near future, with initial patient dosing expected in early 2026.

• Uncertainty in clinical trial results, including potential failure to meet expectations. - Impact of competition from other companies developing similar drugs or technologies. - Regulatory approval risks, such as potential delays or rejections by regulatory agencies. - Funding needs, as continuous financing is required to support operations and R&D.

Q: Tracking toward an interim event analysis for LP-300 trial?

A: At the December webinar, won't be at 31 events yet as patients are on trial longer, but will report data and insights; tracking to be in early 2026.

Q: Denmark trial status?

A: Approved, IRBs set, project manager assigned, expected to start late December or early January at one site in Denmark.

Q: IND submission for pediatric CNS program?

A: Already prepared to submit, expected in the next few weeks, initial patient dosing expected in early 2026.

Q: withZeta platform status?

A: Will have additional news next week, early rollout expected to be informative with learning, already used internally, and will be available as select demo to collaborators and partners.

Q: 184 indications plan?

A: Plan to figure out the best indication with biggest impact and move into larger scale trials, potentially with partners.